Lugano, Switzerland, October 13th, 2015 - Helsinn Healthcare SA announces that it has entered into a settlement agreement with Dr. Reddy's Laboratories, Inc. to resolve certain patent litigations relating to Helsinn Healthcare's Aloxi® (palonosetron HCl injection) in the United States, where it is currently distributed by Helsinn Healthcare's marketing partner, Eisai Inc.
As a result of the settlement, Dr. Reddy's Laboratories Inc. will be permitted to market a 505(j) generic version of Aloxi® in the United States on September 30, 2018 or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential.
About the Helsinn Group
Helsinn is a family run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 with headquarters in Lugano, Switzerland, Helsinn also has operating subsidiaries in Ireland, the United States and a representative office in China. Helsinn's business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in the therapeutic area of cancer care.
Helsinn Group in‐licenses early‐to‐late stage new chemical entities, completing their development by performing preclinical and clinical studies and associated manufacturing activities. Helsinn then prepares necessary regulatory filings in order to achieve marketing approvals worldwide. Helsinn's products are out‐licensed to its global network of marketing and commercial partners that have been selected for their local market knowledge and high ethical standards. Helsinn supports these partners by providing a full range of product and scientific management services, including commercial, regulatory, and medical marketing advice. In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn’s products are manufactured according to the highest quality, safety, and environmental standards at Helsinn's GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers.
For more information please contact:
Head of Communication & Press Office
PH +41 91-985-21-21